Abstract:Seasonal influenza epidemics occur both in northern and southern hemispheres every year. Despite the differences in influenza virus surface antigens and virulence of seasonal subtypes, manufacturers are well-adapted to respond to this periodical vaccine demand. Due to decades of influenza virus research, the development of new influenza vaccines is relatively straight forward. In similarity with the ongoing coronavirus disease 2019 pandemic, vaccine manufacturing is a major bottleneck for a rapid supply of the billions of doses required worldwide. In particular, egg-based vaccine production would be difficult to schedule and shortages of other egg-based vaccines with high demands also have to be anticipated. Cell culture-based production systems enable the manufacturing of large amounts of vaccines within a short time frame and expand significantly our options to respond to pandemics and emerging viral diseases. In this study, we present an integrated process for the production of inactivated influenza A virus vaccines based on a Madin-Darby Canine Kidney (MDCK) suspension cell line cultivated in a chemically defined medium. Very high titers of 3.6 log(10)(HAU/100 mu l) were achieved using fast-growing MDCK cells at concentrations up to 9.5 x 10(6) cells/ml infected with influenza A/PR/8/34 H1N1 virus in 1 L stirred tank bioreactors. A combination of membrane-based steric-exclusion chromatography followed by pseudo-affinity chromatography with a sulfated cellulose membrane adsorber enabled full recovery for the virus capture step and up to 80% recovery for the virus polishing step. Purified virus particles showed a homogenous size distribution with a mean diameter of 80 nm. Based on a monovalent dose of 15 mu g hemagglutinin (single-radial immunodiffusion assay), the level of total protein and host cell DNA was 58 mu g and 10 ng, respectively. Furthermore, all process steps can be fully scaled up to industrial quantities for commercial manufacturing of either seasonal or pandemic influenza virus vaccines. Fast production of up to 300 vaccine doses per liter within 4-5 days makes this process competitive not only to other cell-based processes but to egg-based processes as well.

The Screening and Mechanism of Influenza-Virus Sensitive MDCK Cell Lines for Influenza Vaccine Production

Reduction in Interferon-Stimulated Genes Contributes to High-Yield Production of Influenza Virus in Suspension MDCK Cells

Transcriptomic Characterization Reveals Attributes of High Influenza Virus Productivity in MDCK Cells.

Metabolic Reprogramming and Alteration of the Redox State in Hyper-Productive MDCK Cells for Influenza a Virus Production.

Production, Passaging Stability, and Histological Analysis of Madin–Darby Canine Kidney Cells Cultured in a Low-Serum Medium

High Yield Production of Influenza Virus in Madin Darby Canine Kidney (MDCK) Cells with Stable Knockdown of IRF7

Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity

Establishment and characterization of a Madin-Darby canine kidney reporter cell line for influenza A virus assays

Highly Efficient Production of an Influenza H9N2 Vaccine Using MDCK Suspension Cells

Rational Design of Medium Supplementation Strategy for Improved Influenza Viruses Production Based on Analyzing Nutritional Requirements of Mdck Cells

Enhancing the yield of seasonal influenza viruses through manipulation of microRNAs in Madin-Darby canine kidney cells

Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines.

Transcriptional Analysis of lncRNA and Target Genes Induced by Influenza A Virus Infection in MDCK Cells

Towards integrated production of an influenza A vaccine candidate with MDCK suspension cells

Tumorigencity decrease in Bcl-xL deficient MDCK cells ensuring the safety for influenza vaccine production

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine

Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor

Optimization of cell culture for H9N2 subtype AIV and establishment of high-yield cell strain

Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study

The Establishment and Validation of the Human U937 Cell Line As a Cellular Model to Screen Immunomodulatory Agents Regulating Cytokine Release Induced by Influenza Virus Infection